714 related articles for article (PubMed ID: 25596250)
1. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.
Morishima Y; Kamisato C
Am J Clin Pathol; 2015 Feb; 143(2):241-7. PubMed ID: 25596250
[TBL] [Abstract][Full Text] [Related]
2. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.
Douxfils J; Chatelain B; Chatelain C; Dogné JM; Mullier F
Thromb Haemost; 2016 Jan; 115(2):368-81. PubMed ID: 26510969
[TBL] [Abstract][Full Text] [Related]
3. Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists.
Honda Y; Morishima Y
Thromb Res; 2015 May; 135(5):958-62. PubMed ID: 25791908
[TBL] [Abstract][Full Text] [Related]
4. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
Hillarp A; Strandberg K; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Lindahl TL
Scand J Clin Lab Invest; 2018; 78(7-8):575-583. PubMed ID: 30278787
[TBL] [Abstract][Full Text] [Related]
5. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
[TBL] [Abstract][Full Text] [Related]
6. Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide.
Siriez R; Evrard J; Dogné JM; Pochet L; Gheldof D; Chatelain B; Mullier F; Douxfils J
Thromb Haemost; 2018 Jul; 118(7):1203-1214. PubMed ID: 29890519
[TBL] [Abstract][Full Text] [Related]
7. Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban.
Noguchi K; Morishima Y; Takahashi S; Ishihara H; Shibano T; Murata M
Blood Coagul Fibrinolysis; 2015 Mar; 26(2):117-22. PubMed ID: 24911450
[TBL] [Abstract][Full Text] [Related]
8. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Honda Y; Kamisato C; Morishima Y
Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
10. Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum.
Siddiqui F; Hoppensteadt D; Jeske W; Iqbal O; Tafur A; Fareed J
Clin Appl Thromb Hemost; 2019; 25():1076029619847524. PubMed ID: 31088146
[TBL] [Abstract][Full Text] [Related]
11. Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect.
Iba T; Emmi M; Hiki M; Nagayama M; Aihara K; Tabe Y; Yuri M; Ohsaka A
Int J Hematol; 2016 Jun; 103(6):665-72. PubMed ID: 26984594
[TBL] [Abstract][Full Text] [Related]
12. In vitro assessment of edoxaban anticoagulant effect in pediatric plasma.
Sinegre T; Zlobecki M; Doré E; Pereira B; Grèze V; Lebreton A
Thromb Res; 2019 Jun; 178():112-118. PubMed ID: 31005667
[TBL] [Abstract][Full Text] [Related]
13. Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.
Tobu M; Iqbal O; Hoppensteadt DA; Shultz C; Jeske W; Fareed J
Clin Appl Thromb Hemost; 2002 Oct; 8(4):325-36. PubMed ID: 12516682
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo reversal of the anticoagulant effects of edoxaban.
Halim AB; Samama MM; Mendell J
Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
[TBL] [Abstract][Full Text] [Related]
15. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
16. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
17. The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban.
Brown KS; Wickremasingha P; Parasrampuria DA; Weiss D; Kochan J; Dishy V; He L; Shi M
Thromb Res; 2015 Oct; 136(4):825-31. PubMed ID: 26298619
[TBL] [Abstract][Full Text] [Related]
18. How the direct oral anticoagulant apixaban affects thrombin generation parameters.
Tripodi A; Padovan L; Veena C; Scalambrino E; Testa S; Peyvandi F
Thromb Res; 2015 Jun; 135(6):1186-90. PubMed ID: 25895845
[TBL] [Abstract][Full Text] [Related]
19. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
20. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
